Germany's BioNTech SE (BNTX) reported Tuesday a loss in its fourth quarter, compared to prior year's profit, hurt by weak revenues. Looking ahead for fiscal 2026, the company projects lower revenues.
The quarterly results and outlook reflect weak demand for COVID-19 vaccines.
In pre-market activity on Nasdaq, the shares of the immunotherapy company were plunging around 18.3 percent, trading at $83.48.
For the fourth quarter, net loss was 305.0 million euros, compared to a net income of 259.5 million euros a year ago. Loss per share was 1.25 euros, compared to earnings per share of 1.08 euros last year.
Adjusted net loss was 79.5 million euros or 0.33 euro per share, compared to an adjusted net profit of 432.4 million euros or 1.79 euros per share a year earlier.
Revenues for the three months were 907.4 million euros, compared to 1.19 billion euros in the prior year period.
The quarterly year-on-year decrease was primarily driven by lower sales of the Company's COVID-19 vaccines due to reduced market demand.
Looking ahead for fiscal 2026, the company projects total revenues of 2.0 billion euros to 2.3 billion euros, compared to 2.87 billion euros in fiscal 2025.
In 2026, BioNTech anticipates lower COVID-19 vaccine revenues, driven by declines in both the European and United States markets.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.